Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

BACKGROUND: Sarilumab, an IL-6 receptor antagonist, is a first-line biologic disease-modifying anti-rheumatic drug for rheumatoid arthritis. The identification of genetic biomarkers as predictors of response to sarilumab could allow for a personalized treatment strategy to improve clinical outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Sainz, Luis, Riera, Pau, Moya, Patricia, Bernal, Sara, Casademont, Jordi, Díaz-Torné, Cesar, Millán, Ana Milena, Park, Hye Sang, Lasa, Adriana, Corominas, Hector
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668502/
https://www.ncbi.nlm.nih.gov/pubmed/38001504
http://dx.doi.org/10.1186/s13075-023-03209-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668502/
https://www.ncbi.nlm.nih.gov/pubmed/38001504
http://dx.doi.org/10.1186/s13075-023-03209-1

Ejemplares similares